Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy

Current Oncology

Volumn 8, Issue 2, 2001, Pages 69-82

  Warr, D ^a   Bramwell, V ^a   Anderson, D ^a   Charette, M ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; FLUOROURACIL; GRANISETRON; IFOSFAMIDE; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NAUSEA; PRACTICE GUIDELINE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0034752183     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
2. The Practice Guidelines Development Cycle: A conceptual tool for practice guidelines development and implementation
3. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis
4. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy induced nausea and vomiting: Results of a meta-analysis of randomised controlled trials
5. A meta-analysis of randomised trials evaluating ondansetron (O), granisetron (G) and tropisetron (T)
6. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
7. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomised parallel study
8. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy
9. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study
10. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer
11. Phase III double blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy
12. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomised, parallel-group study
13. A double blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference
14. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
15. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
16. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy
17. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
18. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
19. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study
20. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomised comparative trial of ondansetron versus placebo
21. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis
22. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group
23. The delayedemesis syndrome from cisplatin: Phase-III evaluation of ondansetron versus placebo
24. 3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
25. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis
26. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
27. Ondansetron versus metoclopramide, both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis
28. SAKK 90/95: A randomised double-blind trial to compare the clinical efficacy of granisetron to metoclopramide, both combined to dexamethasone in the prophylaxis of chemotherapy induced delayed emesis
29. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study
30. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomised trial
31. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy: A randomised study
32. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomised controlled trial
33. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens
34. 3-receptor-antagonist in moderately emetogenic chemotherapy
35. 3 receptor antagonists, a new approach in emesis - A review of ondansetron, granisetron and tropisetron
36. Stratified, randomised, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting
37. 3 receptor antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
38. Optimal IV dolasetron dose for prevention of nausea & vomiting (NV) after cisplatin (CDDP) chemotherapy: Analysis of mg doses from 14 pooled trials
39. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy
40. Randomised, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy
41. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy
42. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
43. Controlling delayed vomiting: Double-blind, randomised trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
44. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy
45. Randomised, double-blind comparison of ondansetron versus ondansetron plus metopimazine as anti-emetic prophylaxis during platinum-based chemotherapy in patients with cancer
46. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy
47. Prophylaxis of delayed nausea and vomiting after cancer chemotherapy
48. Role of maintenance dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy